Misplaced Pages

Asandeutertinib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyNext edit →Content deleted Content addedVisualWikitext
Revision as of 17:30, 30 December 2024 editBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 edits created drug stubTag: nowiki added  Revision as of 17:32, 30 December 2024 edit undoBoghog (talk | contribs)Autopatrolled, Extended confirmed users, IP block exemptions, New page reviewers, Pending changes reviewers, Rollbackers, Template editors137,805 editsm typoNext edit →
Line 117: Line 117:
] ]
] ]
] ]
] ]
] ]

Revision as of 17:32, 30 December 2024

Pharmaceutical compound
Asandeutertinib
Clinical data
Other namesRunnor-9591, TY 9591
Identifiers
IUPAC name
  • N--4-methoxy-5-pyrimidin-2-yl]amino]phenyl]prop-2-enamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC28H30D3N7O2
Molar mass502.636 g·mol
3D model (JSmol)
SMILES
  • C()()N1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
InChI
  • InChI=InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)/i5D3
  • Key:DUYJMQONPNNFPI-VPYROQPTSA-N

Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties. Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations.

References

  1. ^ "Asandeutertinib". PatSnap.
  2. "Asandeutertinib". IUPHAR/BPS Guide to PHARMACOLOGY.
  3. Han B, Zhang W, Wu L, Chen B, Zhao Y, Liu J, et al. (October 2024). "P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation". Journal of Thoracic Oncology. 19 (10): S195. doi:10.1016/j.jtho.2024.09.353.
Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: